Product NDC: | 0409-5082 |
Proprietary Name: | Tazicef |
Non Proprietary Name: | CEFTAZIDIME |
Active Ingredient(s): | 1 g/1 & nbsp; CEFTAZIDIME |
Administration Route(s): | INTRAMUSCULAR; INTRAVENOUS |
Dosage Form(s): | INJECTION, POWDER, FOR SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0409-5082 |
Labeler Name: | Hospira, Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA062662 |
Marketing Category: | ANDA |
Start Marketing Date: | 20120305 |
Package NDC: | 0409-5082-16 |
Package Description: | 25 VIAL in 1 TRAY (0409-5082-16) > 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL |
NDC Code | 0409-5082-16 |
Proprietary Name | Tazicef |
Package Description | 25 VIAL in 1 TRAY (0409-5082-16) > 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL |
Product NDC | 0409-5082 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | CEFTAZIDIME |
Dosage Form Name | INJECTION, POWDER, FOR SOLUTION |
Route Name | INTRAMUSCULAR; INTRAVENOUS |
Start Marketing Date | 20120305 |
Marketing Category Name | ANDA |
Labeler Name | Hospira, Inc. |
Substance Name | CEFTAZIDIME |
Strength Number | 1 |
Strength Unit | g/1 |
Pharmaceutical Classes | Cephalosporin Antibacterial [EPC],Cephalosporins [Chemical/Ingredient] |